This investigation looks into a contentious deal between a major pharmaceutical firm and the Guatemalan Social Security Institute (IGSS).

Following the deal, which prosecutors said the IGSS greenlit despite the firm’s lack of experience and infrastructure, dozens of patients with kidney disease died and scores of others were infected. The case would eventually reach the country’s highest courts where the elites implicated in the IGSS case had bought what some said was an insurance policy to make sure they would never be prosecuted.

Investigation Chapters